Yamada Katsuya, Hakura Atsushi, Kato Taka-Aki, Mizutani Takaharu, Saeki Ken-Ichi
Graduate School of Pharmaceutical Sciences, Nagoya City University, Tanabedori, Mizuho-ku, Nagoya 467-8603, Japan.
Mutat Res. 2005 Sep 5;586(1):87-95. doi: 10.1016/j.mrgentox.2005.06.006.
Nitrogen-containing analogs of chrysene, 1,10-diazachrysene (1,10-DAC) and 4,10-DAC, were tested for mutagenicity in Salmonella typhimurium TA100 in the presence of rat liver S9 and human liver microsomes to investigate the effect of nitrogen-substitution. Although these DACs could not be converted to the bay-region diol epoxide because of their nitrogen atoms in the bay-region epoxide or diol moiety, DACs were mutagenic in the Ames test with rat liver S9. Both DACs also showed mutagenicity in the Ames test using pooled human liver microsomes, although chrysene itself was not mutagenic in the presence of pooled human liver microsomes. The mutagenicity of DACs (50nmol/plate) in Ames tests using human liver microsome preparations from 10 individuals was compared with cytochrome P450 (CYP) activity in each microsome preparation to investigate the CYP isoform involved in the activation of DACs to the genotoxic forms. The numbers of induced revertants obtained by 1,10-DAC varied 6.2-folds (109-680) and those by 4,10-DAC 4.8-folds (155-751) among the 10 individuals. The number of induced revertants obtained by 1,10-DAC significantly correlated with the CYP1A2-selective catalytic activity (r=0.84, P<0.01) in each microsome preparation. On the other hand, the number of induced revertants obtained by 4,10-DAC significantly correlated with the combined activity of CYP2A6 and 1A2 (CYP2A6+0.51xCYP1A2; r=0.75, P<0.01). However, in Ames tests using microsomes from insect cells expressing various human CYP isoforms, the mutagenicity of 1,10-DAC was induced only by recombinant human CYP1A2, whereas both recombinant human CYP2A6 and 1A2 contributed to the mutagenicity of 4,10-DAC. These results suggest that 1,10-DAC shows the mutagenicity through involvement of CYP1A2 in human liver, and 4,10-DAC does so through both CYP2A6 and 1A2. In conclusion, our results suggested that the difference in the nitrogen-substituted position in the chrysene molecule might affect the mutagenic activity through influencing the ratio of participation of the metabolic activation enzyme isoforms of CYP.
对屈的含氮类似物1,10 - 二氮杂屈(1,10 - DAC)和4,10 - DAC,在大鼠肝S9和人肝微粒体存在的情况下,于鼠伤寒沙门氏菌TA100中进行致突变性测试,以研究氮取代的影响。尽管由于这些DACs在湾区环氧化物或二醇部分含有氮原子,无法转化为湾区二醇环氧化物,但DACs在使用大鼠肝S9的艾姆斯试验中具有致突变性。两种DACs在使用人肝微粒体混合液的艾姆斯试验中也显示出致突变性,尽管屈本身在人肝微粒体混合液存在时不具有致突变性。在使用来自10个人的人肝微粒体制剂进行的艾姆斯试验中,比较了DACs(50nmol/平板)的致突变性与各微粒体制剂中的细胞色素P450(CYP)活性,以研究参与将DACs激活为遗传毒性形式的CYP同工酶。在这10个人中,1,10 - DAC诱导的回复突变体数量变化了6.2倍(109 - 680),4,10 - DAC诱导的回复突变体数量变化了4.8倍(155 - 751)。1,10 - DAC诱导的回复突变体数量与各微粒体制剂中的CYP1A2选择性催化活性显著相关(r = 0.84,P < 0.01)。另一方面,4,10 - DAC诱导的回复突变体数量与CYP2A6和1A2的联合活性(CYP2A6 + 0.51×CYP1A2;r = 0.75,P < 0.01)显著相关。然而,在使用表达各种人CYP同工酶的昆虫细胞微粒体进行的艾姆斯试验中,1,10 - DAC的致突变性仅由重组人CYP1A2诱导,而重组人CYP2A6和1A2均对4,10 - DAC的致突变性有贡献。这些结果表明,1,10 - DAC通过人肝中的CYP1A2参与而表现出致突变性,4,10 - DAC则通过CYP2A6和1A2两者表现出致突变性。总之,我们的结果表明,屈分子中氮取代位置的差异可能通过影响CYP代谢激活酶同工酶的参与比例而影响致突变活性。